Monopar Therapeutics Inc. (MNPR) Cash Flow Statement
Monopar Therapeutics Inc. (MNPR) generated -$12.2M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$12.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MNPRMonopar Therapeutics Inc.Follow MNPR — free
—
Price chart with a free account
- Market cap
- 474.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -2.6 | -2.7 | -3.0 | -4.7 | -7.3 | -7.2 | -7.9 | -6.4 | -12.2 | -12.2 | |
| Capital expenditure | — | — | — | — | — | — | — | 0.0 | 0.0 | -0.0 | |
| Free cash flow | — | — | — | — | — | — | — | -6.4 | -12.2 | -12.2 | |
| Share repurchases | — | — | — | — | — | — | — | 0.0 | 35.0 | — | |
| Stock-based compensation | — | — | — | — | — | — | 1.9 | 1.1 | 4.8 | — |
USD millions · SEC XBRL
Monopar Therapeutics Inc. — questions
- What is Monopar Therapeutics Inc.'s operating cash flow?
- -$12.2M over the twelve months to 2026-06-30.
- How much does Monopar Therapeutics Inc. spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Monopar Therapeutics Inc.'s free cash flow?
- -$12.2M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Monopar Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.